ISIS Pharmaceuticals (ISIS) Bullish Stance Reiterated at BMO Capital Post Q1
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Piper Jaffray Upgrades ISIS Pharmaceuticals (ISIS) to Overweight
May 6, 2014 3:22 PM EDTPiper Jaffray upgraded ISIS Pharmaceuticals (NASDAQ: ISIS) from Neutral to Overweight.
For an analyst ratings summary and ratings history on ISIS Pharmaceuticals click here. For more ratings news on ISIS Pharmaceuticals click here.
Shares of ISIS Pharmaceuticals closed at $25.60 yesterday.
... MoreIsis Pharmaceuticals, Inc. (ISIS) Misses Q1 EPS by 4c
May 6, 2014 8:35 AM EDTIsis Pharmaceuticals, Inc. (NASDAQ: ISIS) reported Q1 EPS of ($0.27), $0.04 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $28.2 million versus the consensus estimate of $35.12 million.
On a GAAP basis, Isis reported a loss from operations of $29.7 million for the three months ended March 31, 2014 compared to income from operations of $1.6 million for the same period in 2013. Isis maintained its strong cash position and ended the first quarter of 2014 with approximately $631 million in cash compared to $657 million at December 31, 2013.
"In the first quarter we have accomplished a number of... More
